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Abstract
A volumeeoutcome relationship has been shown in adult oncology. We investigated if an inverse association of
volume and death exists in pediatric acute lymphoblastic leukemia (ALL) care. In assessing the association of
volume and outcomes in a cohort of hospitalized pediatric ALL patients, we did not show an inverse rela-
tionship between volume and mortality or need for intensive care.
Background: There are few contemporary studies of volumeeoutcome relationships in pediatric oncology. Children
with acute lymphoblastic leukemia (ALL) are treated at a wide variety of hospitals. We investigated if inpatient
hospital volume inﬂuences outcomes. The objective of this study was to evaluate the relationship between inpatient
pediatric and pediatric oncology volume and mortality and intensive care resources (ICU care). We hypothesized an
inverse relationship between volume and these outcomes. Patients and Methods: This was a retrospective cohort
study. Patients 0 to 18 years of age in the Pediatric Health Information System or Perspective Premier Database
from 2009 to 2011 with ALL were included. Exposures were considered as the average inpatient pediatric and
pediatric oncology volume. The primary outcome was inpatient mortality; secondary outcome was need for ICU
care. Results: The included population comprised 3350 patients from 75 hospitals. The inpatient mortality rate was
0.86% (95% conﬁdence interval, 0.58%-1.2%). In the unadjusted analysis, mortality increased as pediatric
oncology volume increased from low (0%) to high volume (1.3%) (P ¼ .009). The small number of deaths precluded
multivariable analysis of this outcome. Pediatric and pediatric oncology volume was not associated with ICU care
when we controlled for potential confounders. Conclusion: Induction mortality was low. We did not observe an
inverse relationship between volume and mortality or ICU care. This suggests that in a modern treatment era,
treatment at a low-volume center might not be associated with increased mortality or ICU care in the ﬁrst portion ofPreliminary data were presented at the 56th Annual American Society of Hematology
Meeting and Exposition, December 7, 2014, San Francisco, California.
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therapy. This relationship should be evaluated in other oncology populations with higher mortality rates and with
longer-term outcomes.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 16, No. 7, 404-10 ª 2016 The Author(s). Published by Elsevier Inc. This is an
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Volumeeoutcome relationships associate the amount of care
provided at a hospital level to the quality of care received by an
individual patient.1 These relationships have been studied exten-
sively in procedural ﬁelds, and an inverse relationship between
volume and patient mortality found.2,3 Studies in adult oncology
have suggested that higher-volume centers have better outcomes for
surgical and nonsurgical management.4-6 In pediatric oncology, a
volumeeoutcome relationship has been less well examined. A sys-
tematic review undertaken to evaluate volume in pediatric oncology
concluded that higher volumes are related to better survival.7
However, the generalizability of this ﬁnding might be limited by
the heterogeneity of the cancer populations included and of the
deﬁnitions of the volume exposures.7 More recent studies focused
on speciﬁc pediatric tumors including Wilms tumor and neuro-
blastoma did not ﬁnd a relationship between volume and
outcome.8,9 The potential effect of a volumeeoutcome association
across different types of pediatric malignancy is needed because the
ﬁndings might help either optimize the provision of care for these
patients, or help to reinforce current practice.
Acute lymphoblastic leukemia (ALL) is the most common pe-
diatric malignancy and, therefore, represents an important group in
which to investigate the volumeeoutcome paradigm. It is estimated
that thirty-ﬁve hundred pediatric patients will be diagnosed with
ALL in the United States in 2016.10 Fortunately, remarkable im-
provements in survival have occurred in recent decades, resulting in
a 90% survival rate.11 The improvement in survival has been ach-
ieved via optimization of risk classiﬁcation and intensiﬁcation of
chemotherapy. This has led to well established, but complex,
treatment protocols that require comprehensive hospital services.
Previous studies of the volumeeoutcome relationship among chil-
dren with ALL did suggest an association, but this represented an
earlier era of therapy.12 Currently, there are a number of established
protocols for the management of ALL that might reduce variation in
outcomes. However, recent data suggest that mortality among
children with ALL continues to vary according to insititution.13 It is
possible that this variation in mortality might be related to hospital
volume. A better understanding of the volumeeoutcome associa-
tion across different types of pediatric malignancy is needed. We
hypothesized that mortality and need for intensive care resources
(ICU care) during the period of ALL induction chemotherapy
would be inversely related to a hospital’s volume of inpatient pe-
diatric and pediatric oncology patients.
Patients and Methods
Overview and Study Design
A retrospective cohort study of patients with new-onset ALL was
performed with 2009 to 2011 data from the Pediatric HealthInformation System (PHIS) and Perspective Data Warehouse
(Premier Inc, Charlotte, NC). Forty-one hospitals from PHIS, and
34 hospitals from Premier were included. The institutional review
board of the Children’s Hospital of Philadelphia reviewed the study
and determined exempt status.
Data Sources
The PHIS database has previously been described in detail.14,15
Brieﬂy, PHIS includes administrative and billing data from 46
freestanding, noncompeting, not for proﬁt tertiary children’s hos-
pitals across the United States. PHIS data include demographic
characteristics, dates of service, discharge disposition, International
Classiﬁcation of Diseases, Ninth Revision (ICD-9) discharge diag-
nosis and procedure codes, and detailed billed resource utilization
information. Data are deidentiﬁed at the time of submission and
subjected to reliability and validity checks. Data quality is assured
through a combined effort between the Children’s Hospital Asso-
ciation (Overland Park, KS), Truven Health Analytics, and
participating hospitals.
Perspective Data Warehouse, maintained by Premier, Inc
(Charlotte, NC) is a large administrative database representative of a
distinct consortium of US not for proﬁt hospitals. Hospitals
contributing to the Premier database include academic and com-
munity hospitals. These institutions represent one-sixth of all hos-
pitalizations in the United States. Importantly, although PHIS
hospitals are dedicated children’s hospitals, hospitals in Premier
admit children and adults. Data elements in Premier are similar to
those found in PHIS and include demographic and hospitalization
data, ICD-9 discharge diagnoses and procedures codes, pharmacy
billing data, and charges.16
Study Cohort
A previously established and validated inpatient cohort of pedi-
atric ALL patients from PHIS was extended to include the years
under study.14 A parallel cohort was constructed from Premier using
the same steps applied to assemble the PHIS cohort. In brief, all
patients younger than 19 years of age with a discharge ICD-9 code
for ALL (204.xx) were identiﬁed. Pharmacy billing records were
reviewed for medications and timing consistent with known ALL
induction chemotherapeutic regimens. We restricted the study
population to 2009 to 2011 to use parallel years from each data
source. Patients with an ICD-9 code for trisomy 21 (758.0) were
excluded because of potential for differential morbidity, mortality,
and clinical practice in this population. There were 2 hospitals that
contribute to Premier and PHIS. Data for these hospitals from
Premier were omitted to avoid duplicate patients (see Supplemental
Figure 1 in the online version). Of note, only 1 patient had a
discharge status that was unknown.Clinical Lymphoma, Myeloma & Leukemia July 2016 - 405
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The a priori primary outcome of interest was inpatient mortality
in the ﬁrst 60 days after initial admission containing induction
chemotherapy. The secondary outcome was receipt of ICU care at
any time after the ﬁrst 2 admission days and up to day 60. Both
outcomes were dichotomous. ICU care was deﬁned using resource
utilization data, rather than location. These deﬁnitions included
clinical resources used, medication bills, and ICD-9 procedure codes
separated into the following categories: cardiovascular, respiratory,
hemodialysis, leukapheresis, and neurologic. ICU care identiﬁcation
according to these deﬁnitions of resource allocation has been pre-
viously described by our research group.17 Patients receiving ICU
care resources in the ﬁrst 2 days of admission were excluded from
the ICU care outcome analysis because the need for ICU care after
the ﬁrst 2 days might reﬂect severity of illness at presentation rather
than quality of care provided.
Primary Independent Variables (Exposures)
Hospital pediatric volume was calculated as the average number
of pediatric hospitalizations (1-19 years of age) per year and cate-
gorized as low (<7000), medium (7000-11,000) and high
(>11,000) on the basis of the distribution of volume. Pediatric
oncology volume was calculated in a similar manner and categorized
as low (<650), medium (650-1500), and high (>1500). Pediatric
oncology admissions were identiﬁed using Complex Chronic
Condition (CCC) codes for malignancy.18
Patient and Hospital-Level Covariates
Patient-level covariates included age, race, sex, requirement of
ICU care during the ﬁrst 2 days of admission (for mortality
analysis only), and number of days hospitalized during the 60 days
from the index admission date. Hospital-level factors included
teaching status, deﬁned as whether a hospital had any training
programs, and census region. Data on proportion of public in-
surance was collected as a percentage of total admissions to a
hospital for which a patient had an indication of public insurance.
Hospital transfer rates were also recorded. Laboratory values were
not available for analysis.
Statistical Analysis
Descriptive statistics were calculated using frequencies and me-
dians with interquartile ranges. Bivariate analyses using Fisher exact
test, were performed to compare the distribution of the patient- and
hospital-level covariates according to volume categories. Mortality
rates are presented as number of events per 100 patients.
Nonparametric trend testing was performed to evaluate mortality
rates across volume categories. Generalized estimating equations
accounting for clustering within institutions was performed to es-
timate the population-averaged association between patient volume
and the probability of using ICU care.19 Clustering was evaluated
because of the potential for unmeasured characteristics at the
institution level that might be associated with hospital volume and
the outcome of interest.20,21 For each model, adjusted coefﬁcients
were estimated by including all relevant patient- and hospital-level
covariates. Manual selection of covariates for inclusion in the ﬁnal
models was on the basis of a signiﬁcance level of P < .2. MarginalClinical Lymphoma, Myeloma & Leukemia July 2016probabilities of each outcome at the different levels of volume were
estimated from these models.19
Sensitivity analyses used trend analysis for proportions between
volume categories. All analyses were performed using STATA 13
(StataCorp LP, College Station, TX).
Results
Patient and Hospital Characteristics
A cohort of 3350 pediatric patients with ALL from 75 hospitals
was assembled from the PHIS and Premier data sources (see
Supplemental Figure 1 in the online version). The distribution of
hospital and patient characteristics according to pediatric volume
and pediatric oncology volume categories is represented in
Tables 1 and 2. Table 1 represents distribution of patients
according to the hospital characteristics of teaching status and
census region. The number of teaching hospitals varied according
to pediatric oncology volume. Median public insurance rates at
each hospital did not differ according to pediatric hospital volume
but increased as pediatric oncology volume increased. Age and sex
were similar across volume categories (Table 2). Race distribu-
tions differed according to overall pediatric volume, but not by
pediatric oncology volume. The median number of inpatient days
in the 60 days from presentation varied across pediatric volume
categories but was similar across pediatric oncology volume
categories.
Mortality Outcome
Twenty-nine patients died within 60 days of initial ALL diag-
nosis (0.86% of the cohort; 95% conﬁdence interval [CI],
0.58%-1.2%). Most deaths occurred within 3 weeks of the index
admission (see Supplemental Figure 2 in the online version).
Although mortality rates appeared to be least in the lowest-volume
category, the mortality rates were not statistically signiﬁcantly
different according to pediatric volume (0.30% for low, 1.01% for
medium, and 0.99% for high; P ¼ .184; Figure 1A). However,
mortality rates increased in association with the increase in hospital
pediatric oncology volume, from 0% in the low-volume, 1.02% in
the medium-volume, and 1.30% in the high-volume (P ¼ .009;
Figure 1B). Because of the few deaths, we were unable to perform
traditional adjusted analyses for potential confounders, at the
patient level and at the hospital level. Similar to previous publica-
tions from our group, the raw number of deaths peaked during the
third week of induction (see Supplemental Figure 2 in the online
version).
Because multivariate modeling could not be performed because
of the small number of deaths, additional sensitivity analyses were
performed to further assess the association of volume and mortality.
These sensitivity analyses sought to address the following issues:
potential for differential loss of follow-up because of patient transfer
out of a hospital, variation in patient complexity at time of diagnosis
and outcome, and differential capture of exposure and outcome
according to data source. In total, 15 of 3350 patients transferred
during the 60-day follow-up period (0.45%; 95% CI, 0.22%-
0.67%). Although this rate is low, signiﬁcantly higher transfer rates
occurred at the low-volume pediatric oncology hospitals (1.15%)
versus the medium- and high-volume pediatric oncology hospitals
Table 1 Hospital Characteristics (75 Hospitals)
Characteristic
Value
PTotal
Low (<7000;
33 Hospitals)
Medium (7000-11,000;
34 Hospitals)
High (>11,000;
8 Hospitals)
Pediatric Volume
Teaching hospital 65 (87) 28 (85) 30 (88) 7 (87.5) .730
Census region .110
West 16 (21) 5 (15) 11 (32) 0 (0)
Midwest 16 (21) 6 (18) 8 (24) 2 (25)
South 31 (41) 17 (51) 10 (29) 4 (50)
Northeast 12 (16) 5 (15) 5 (15) 2 (25)
Median proportion public insurance (IQR) 0.54 (0.46-0.62) 0.55 (0.45-0.62) 0.54 (0.46-0.63) 0.53 (0.46-0.59) .74
Pediatric Oncology Volume Total Low (<650;
40 Hospitals)
Medium (650-1500;
29 Hospitals)
High (>1500;
6 Hospitals)
Teaching hospital 65 (87) 31 (77.5) 28 (96.6) 6 (100) .018
Census region .020
West 16 (21) 6 (15) 9 (31) 1 (17)
Midwest 16 (21) 7 (17.5) 9 (31) 0 (0)
South 31 (41) 19 (47.5) 9 (31) 3 (50)
Northeast 12 (16) 8 (20) 2 (7) 2 (33)
Median proportion public insurance (IQR) 0.54 (0.46-0.62) 0.51 (0.43-0.55) 0.55 (0.46-0.63) 0.59 (0.53-0.73) .001
Data are presented as n (%) except where otherwise mentioned.
Abbreviation: IQR ¼ interquartile range.
Jennifer J. Wilkes et al(0.25% and 0.29%, respectively; P ¼ .016; Figure 1B). No statis-
tically signiﬁcant difference in transfer was seen in ordered groups
according to general pediatric volume, with rates of transfer at low-
volume institutions of 0.61%, 0.40% for medium-volume, and
0.28% for high-volume institutions (Figure 1A). With this variation
in transfer rate according to pediatric oncology volume levels, we
further explored the potential effect of transfers on the vol-
umeeoutcome association. If half of the patients transferred were
assumed to die, an increasing mortality trend over categories of
pediatric oncology volume was apparent but not statisticallyTable 2 Patient Characteristics (n [ 3350; 75 Hospitals)
Characteristic Total
Low (<7000; 33 Hospitals
n [ 658)
Pediatric Volume
Median age (IQR), years 5 (3-9.9) 4.7 (3-9.9)
Male sex 1873 (56) 383 (58)
White race 2292 (68) 487 (74)
Median days in hospital (IQR) 14 (10-24) 15 (10-25)
Pediatric Oncology Volume Low (<650; 40 Hospitals;
n [ 695)
Median age (IQR), years 4.7 (3-9.8)
Male sex 399 (57)
White race 472 (68)
Median days in hospital (IQR) 14 (10-24)
Data are presented as n (%) except where otherwise noted.
Abbreviation: IQR ¼ interquartile range.
aP < .05.signiﬁcant (0.46% for low-volume, 1.10% for medium-volume, and
1.30% for high-volume institutions; P ¼ .140). Alternatively, we
assumed pessimistically that all patients who required ICU care at
the time of transfer died. With this assumption, the population
averaged mortality rates for low, medium, and high pediatric
oncology volume hospitals were 0.4%, 1.10%, and 1.45%,
respectively (P ¼ .059 for nonparametric trend).
The second sensitivity analysis was conducted to assess whether
potential variation across hospitals of patient complexity occurred
at the time of diagnosis. Our hypothesis was that patientsValue
P Value for
Differences
; Medium (7000-11,000;
34 Hospitals; n [ 1982)
High (>11,000; 8
Hospitals; n [ 710)
5 (3-9.9) 4.9 (3.1-9.8) .528
1091 (55) 399 (56) .472
1282 (65) 523 (74) <.01a
13 (9-22) 16.5 (10-31) <.01a
Medium (650-1500;
29 Hospitals; n [ 1922)
High (>1500;
6 Hospitals; n [ 690)
4.9 (3-9.6) 5.2 (3-10.5) .406
1095 (56) 379 (55) .781
1367 (70) 453 (66) .299
14(10-24) 15 (9-28) .282
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Figure 1 (A) Unadjusted Mortality and Transfer According to
Pediatric Volume With 95% CIs. (B) Unadjusted
Mortality and Transfer According to Pediatric
Oncology Volume With 95% CIs
Table 3 Unadjusted and Adjusted Odds Ratios of ICU Utiliza-
tion According to Volume Category Adjusted for Age,
Length of Stay, Data Source, and Teaching Status
Volume Category
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Pediatric Volume
Low Reference Reference
Medium 1.00 (0.72-1.38) 1 (0.70-1.45)
High 1.51 (1.00-2.28) 1.00 (0.53-1.87)
Pediatric Oncology Volume
Low Reference Reference
Medium 1.63 (1.10-2.41) 1.61 (0.81-3.21)
High 1.93 (1.29-2.91) 1.44 (0.65-3.21)
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line, and this complexity could increase inductionmortality.We used
previously established CCC codes deﬁned according to ICD-9
diagnosis codes to identify underlying chronic conditions other
than malignancy.18 There were 2657 patients from 74 hospitals who
had no chronic care condition other than malignancy identiﬁed. In
patients without an underlying chronic care condition, mortality rates
according to group ranged from 0% (97.5%CI, 0%-0.5%) in the low
pediatric oncology volume group, 1% (95% CI, 0.5%-1.5%) in the
medium pediatric oncology volume group, and 1.12% (95% CI,
0.2%-2%) in the high pediatric oncology volume group (P ¼ .039).
There was still no trend across the groups of pediatric volume and
mortality, with mortality of 0.3% (95% CI, 0%-0.9%) in the low-,
1% (95% CI, 0.5%-1.5%) in the medium-, and 0.7% (95% CI,
0.02%-1.4%) in the high-volume pediatric institutions.Clinical Lymphoma, Myeloma & Leukemia July 2016Because of the potential for unobserved heterogeneity between
PHIS and Premier data, a third sensitivity analysis was conducted
using each data source alone. The relationship of increasing mor-
tality with increasing pediatric oncology volume was statistically
nonsigniﬁcant, with mortality rates of 0% in low-, 1.00% in me-
dium-, and 1.45% in high-volume pediatric oncology centers (P ¼
.083). In PHIS pediatric centers, mortality also did not statistically
signiﬁcantly differ according to pediatric volume category with
0.40% at low-, 1.10% at medium-, and 1.20% at high-volume
pediatric centers (P ¼ .254). In an analysis limited to Premier, of
535 patients, only 1 patient died during the 60-day follow-up
period. Despite this low mortality, 6 patients were transferred
from low-volume pediatric oncology institutions.
Intensive Care Unit Resources
As a secondary outcome we investigated whether volume category
was associated with the receipt of ICU care after the ﬁrst 2 hospital
days. There were 24 patients who received ICU care at the time of
or within 2 days of the initial admission. To distinguish between
potential severity of illness at presentation and worsening clinical
status after admission, we excluded the 24 patients who required
ICU care in the ﬁrst 2 days. In the remaining cohort, there were 279
of 3326 (8.4%; 95% CI, 7.4%-9.3%) patients who progressed to
need at least 1 day of ICU care. In unadjusted analysis, there was a
higher rate of ICU care utilization as pediatric oncology volume
increased (Table 3). After adjustment for number of days in hos-
pital, age, resident teaching status, hospital public insurance pro-
portion, and data source, there was no difference between pediatric
and pediatric oncology volume categories in the need for at least 1
day of ICU care in the ﬁrst 60 days of the index admission. The
marginal probability estimates for need of ICU care was similar
across pediatric volume categories and ranged from 0.04 to 0.063 in
low-volume pediatric oncology hospitals to high-volume pediatric
oncology hospitals (Figure 2). There was also no difference among
the volume categories if patients who had required ICU care at
admission were included.
Discussion
In this large, nationally representative sample of US hospitals, we
analyzed the relationship between hospital volume and mortality
Figure 2 Marginal Probability of Intensive Care Resources
According to Volume Category Adjusted for Age,
Length of Stay, Data Source, and Teaching Status
Jennifer J. Wilkes et alduring the induction period for pediatric ALL. The overall induc-
tion mortality rate of 0.86% in this cohort is consistent with recent
literature.11,13 We hypothesized that a hospital’s volume of pediatric
patients and pediatric oncology patients would be inversely associ-
ated with mortality. However, in unadjusted analyses of trend ac-
cording to ordered group, mortality rates did not signiﬁcantly vary
across the 3 pediatric volume categories, whereas mortality increased
as pediatric oncology volume increased. Similar to previous publi-
cations from our group, the raw number of deaths peaked during
the third week of induction (see Supplemental Figure 2 in the
online version), a ﬁnding which likely coincides with the period of
neutropenia.
These unadjusted ﬁndings might be confounded by the fact that
hospitals with higher pediatric oncology volume are more likely to
care for patients who are acutely ill at presentation and might be
more likely to have an underlying complex chronic condition at the
time of presentation of their ALL. Alternatively, lower-volume
hospitals might be more likely to transfer critically ill ALL pa-
tients before death. Because of the few deaths, we were unable to
perform traditional adjusted multivariate analysis of the mortality
outcome. Therefore, sensitivity analyses were performed to address
patient transfers, presence of a chronic condition, and data source.
Each of these sensitivity analyses reduced the trend betweenmortality and pediatric oncology volume category but mortality was
not found to be inversely associated with volume as we hypothesized
and in certain circumstances increased volume remained associated
with increased mortality. Likewise, a hospital’s pediatric volume and
pediatric oncology volume was not inversely associated with the
need for ICU care even after adjustments used in multivariate
analysis. It is possible that residual confounding persisted to explain
the lack of an inverse association. Alternatively, it remains possible
that mortality is associated with increasing pediatric oncology vol-
ume. For instance, hospitals that have higher volumes might be
overly taxed and not able to focus on the important details for each
patient.
A few previous studies including pediatric ALL patients have
investigated the volumeeoutcome association. Contrary to our
ﬁndings, Stiller and Draper concluded that the reduction in mor-
tality seen in their study occurred in parallel with increased numbers
of patients treated with standardized protocols.12 It is notable that
the ALL patients from the previous study were cared for during an
earlier decade of pediatric ALL treatment, a period in which
chemotherapy regimens differed from current regimens.7,12 In a
more recent ALL cohort, increases in pediatric ALL volume were
not associated with improved survival.13 Similarly, in another
common pediatric tumor with a low mortality rate, Wilm tumor,
investigation of pediatric patients found that survival was not
associated with volume.8,9
A major strength of the current study was the use of multiple data
sources to examine patients cared for at a broad range of institutions
treating children with cancer. It is the ﬁrst study in ALL to evaluate
hospital pediatric and oncology volume and outcomes in the current
era of treatment. However, our study needs to be interpreted in the
context of its limitations. First, there is the possibility of “selective
referral” in which more complicated patients are treated at higher-
volume centers or sicker patients at lower-volume hospitals are
transferred out of an institution. In either situation, the results
would be biased toward a ﬁnding of worse outcomes at higher
volume centers. We attempted to address these concerns in various
sensitivity analyses, but this bias might have persisted. Identifying
reasons for transfer was not possible from these source data but
would be a topic for further study. Second, the lack of laboratory
results precluded our ability to determine certain biologic-level risk
factors (eg, initial white count, cytogenetics, and minimal residual
disease evaluation) known to inﬂuence mortality. Therefore, we
were unable to adjust for variation in laboratories including pre-
senting white blood cell counts across patients at each volume level.
Third, the study hospitals might over-represent the south census
region, and therefore, limit generalizability of our ﬁndings. Finally,
and likely most importantly, the induction mortality events in this
cohort were rare. Although beneﬁcial for patients and their families,
this precluded the use of multivariable adjustment. When an
adjusted analysis was performed with our secondary outcome, ICU
care, the relationship between volume and outcome seen in unad-
justed rates did not persist. Although the very low inpatient mor-
tality rate limits the ability to adjust for covariates, the low mortality
rate itself across each grouping despite a large cohort argues that this
malignancy can be managed appropriately across these volumes in
induction. However, this result cannot be extrapolated to other
pediatric malignancies.Clinical Lymphoma, Myeloma & Leukemia July 2016 - 409
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In a large sample of US hospitals with different volumes that care for
children with ALL, we did not see higher induction mortality or uti-
lization of ICU care at lower-volume institutions, as we hypothesized.
There was a suggestion of worse outcomes among higher pediatric
oncology volumes for mortality, but not for need for use of ICU care.
Further investigation is needed to conﬁrm our ﬁndings and to identify
factors distinct from hospital volume that might explain variation in
outcomes across institutions. Our ﬁndings are not generalizable
beyond ALL induction or to other pediatric oncology diseases. For
example, hospital volume might be more important in higher-risk
conditions for which care is provided more frequently in the inpa-
tient setting such as patients treated for acute myeloid leukemia or
relapsed leukemia. Speciﬁcally assessing for a volume outcome associ-
ation in these other patient populations is warranted.
Clinical Practice Points
 Patients with pediatric ALL are treated at many different in-
stitutions with varying pediatric and pediatric oncology volumes.
 Unlike in adult oncology cohorts, an inverse relationship be-
tween volume and mortality or volume and need for intensive
care does not appear to exist for children with ALL during the
initiation of treatment.
 These data do not support preferential management of children with
ALL in induction at high-volume centers. Evaluation of the vol-
umeeoutcome association for other pediatricmalignancies is needed.Acknowledgments
The authors thank A. Russell Localio JD, MA, MPH, MS, PhD
for his thoughtful comments.Disclosure
The authors have stated that they have no conﬂicts of interest.
Supplemental Data
Supplemental ﬁgures accompanying this article can be found in
the online version at http://dx.doi.org/10.1016/j.clml.2016.04.016.Clinical Lymphoma, Myeloma & Leukemia July 2016References
1. Luft HS, Hunt SS, Maerki SC. The volumeeoutcome relationship: practice-
makes-perfect or selective-referral patterns? Health Serv Res 1987; 22:157.
2. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A
systematic review and methodologic critique of the literature. Ann Intern Med
2002; 137:511-20.
3. McAteer JP, Lariviere CA, Drugas GT, Abdullah F, Oldham KT, Goldin AB.
Inﬂuence of surgeon experience, hospital volume, and specialty designation on
outcomes in pediatric surgery: a systematic review. JAMA Pediatr 2013; 167:468-
75.
4. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization
and outcomes in cancer treatment: importance in quality of cancer care. J Clin
Oncol 2000; 18:2327-40.
5. Lüchtenborg M, Riaz SP, Coupland VH, et al. High procedure volume is strongly
associated with improved survival after lung cancer surgery. J Clin Oncol 2013; 31:
3141-6.
6. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on
operative mortality for major cancer surgery. JAMA 1998; 280:1747-51.
7. Knops RR, van Dalen EC, Mulder RL, et al. The volume effect in paediatric
oncology: a systematic review. Ann Oncol 2013; 24:1749-53.
8. Gutierrez JC, Koniaris LG, Cheung MC, Byrne MM, Fischer AC, Sola JE. Cancer
care in the pediatric surgical patient: a paradigm to abolish volumeeoutcome
disparities in surgery. Surgery 2009; 145:76-85.
9. Gutierrez JC, Cheung MC, Zhuge Y, Koniaris LG, Sola JE. Does Children’s
Oncology Group hospital membership improve survival for patients with neuro-
blastoma or Wilms tumor? Pediatr Blood Cancer 2010; 55:621-8.
10. A SEER Cancer Statistics Review, 1975-2012. National Cancer Institute; 2015.
National Cancer Institute, Surveillance, Epidemiology and End Results, seer.
cancer.gov. Accessed: July 7, 2015.
11. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents
with acute lymphoblastic leukemia between 1990 and 2005: a report from the
Children’s Oncology Group. J Clin Oncol 2012; 30:1663-9.
12. Stiller CA, Draper GJ. Treatment centre size, entry to trials, and survival in acute
lymphoblastic leukaemia. Arch Dis Child 1989; 64:657-61.
13. Seif AE, Fisher BT, Li Y, et al. Patient and hospital factors associated with induction
mortality in acute lymphoblastic leukemia. Pediatr Blood Cancer 2014; 61:846-52.
14. Fisher BT, Harris T, Torp K, et al. Establishment of an 11-year cohort of 8733
pediatric patients hospitalized at United States free-standing children’s hospitals
with de novo acute lymphoblastic leukemia from health care administrative data.
Med Care 2014; 52:e1-6.
15. Fisher BT, Zaoutis TE, Leckerman KH, Localio R, Aplenc R. Risk factors for renal
failure in pediatric patients with acute myeloid leukemia: a retrospective cohort
study. Pediatr Blood Cancer 2010; 55:655-61.
16. Fisher BT, Lindenauer PK, Feudtner C. In-hospital databases. In: Strom BL,
Kimmel S, Hennessy S, eds. Pharmacoepidemiology. 5th ed. Chicester, UK: John
Wiley & Sons, Ltd; 2012:244-58.
17. Maude SL, Fitzgerald JC, Fisher BT, et al. Outcome of pediatric acute myeloid
leukemia patients receiving intensive care in the United States. Pediatr Crit Care
Med 2014; 15:112-20.
18. Feudtner CC, Christakis DA, Connell FA. Pediatric deaths attributable to
complex chronic conditions: a population-based study of Washington State,
1980-1997. Pediatrics 2000; 106:205-9.
19. Korn E, Graubard B. Analysis of Health Surveys. New York: John Wiley & Sons,
Inc; 1999:127-40.
20. Panageas KS. The effect of clustering of outcomes on the association of procedure
volume and surgical outcomes. Ann Intern Med 2003; 139:658-65.
21. Panageas KS, Schrag D, Localio AR, Venkatraman ES, Begg CB. Properties of
analysis methods that account for clustering in volumeeoutcome studies when the
primary predictor is cluster size. Stat Med 2007; 26:2017-35.
Supplemental Figure 1 Cohort diagram of patient included
and excluded
Abbreviations: ALL ¼ acute lymphoblastic leukemia; ICD9 ¼ International Classiﬁcation of
Diseases, Ninth Revision.
Supplemental Figure 2 By volume category, Raw Numbers of
Deaths by Day of Induction
Jennifer J. Wilkes et al
Clinical Lymphoma, Myeloma & Leukemia July 2016 - 410.e1
